inclusion criteria: * 18 years or older patients * patient with hematologic malignancy who received or not hematopoietic stem cell transplantation * non severe covid-19 disease * pcr-confirmed covid-19 disease by a nasopharyngeal swab * life-expectancy related to the hematologic malignancy of at least 1 month * men or women of child-bearing potential accepting to use effective contraception during and until 8 months after the end of the study treatment

inclusion criteria: * 18 years or older patients * patient with hematologic malignancy who received or not hematopoietic stem cell transplantation * non severe covid-19 disease * pcr-confirmed covid-19 disease by a nasopharyngeal swab * life-expectancy related to the hematologic malignancy of at least 1 month * men or women of child-bearing potential accepting to use effective contraception during and until 8 months after the end of the study treatment

inclusion criteria: - 18 years or older patients - patient with hematologic malignancy who received or not hematopoietic stem cell transplantation - non severe covid-19 disease - pcr-confirmed covid-19 disease by a nasopharyngeal swab - life-expectancy related to the hematologic malignancy of at least 1 month - men or women of child-bearing potential accepting to use effective contraception during and until 8 months after the end of the study treatment

inclusion criteria: - 18 years or older patients - patient with hematologic malignancy who received or not hematopoietic stem cell transplantation - non severe covid-19 disease - pcr-confirmed covid-19 disease by a nasopharyngeal swab - life-expectancy related to the hematologic malignancy of at least 1 month - men or women of child-bearing potential accepting to use effective contraception during and until 8 months after the end of the study treatment